Testicular Germ Cell Tumor Clinical Trial
Official title:
Randomized Phase II/III Study of Taxol/Paclitaxel-BEP Versus BEP in Patients With Intermediate Prognosis Germ Cell Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing
so they stop growing or die. Combining more than one drug may kill more tumor cells. It is
not yet known which regimen of combination chemotherapy may be more effective for germ cell
cancer.
PURPOSE: This randomized phase II/III trial is studying two different regimens of
combination chemotherapy and comparing how well they work in treating men with germ cell
cancer.
OBJECTIVES:
Phase II
- Compare the complete response rates in men with intermediate prognosis germ cell cancer
treated with bleomycin, cisplatin, and etoposide (BEP) vs bleomycin, cisplatin,
etoposide, and paclitaxel (T-BEP).
- Define the toxicity profile of T-BEP in these patients.
Phase III
- Compare the disease-free survival of patients treated with these regimens.
- Compare the complete response rates and overall survival of patients treated with these
regimens.
- Compare symptoms and aspects of quality of life at baseline and after treatment in
patients treated with these regimens.
- Compare the acute and intermediate (1-2 years) side effects of these regimens in these
patients.
OUTLINE: This is a randomized, multicenter study. Patients are stratified according to
histology (seminoma vs non-seminoma) and hospital. Patients are randomized to 1 of 2
treatment arms.
- Arm I: Patients receive cisplatin IV and etoposide IV on days 1-5 and bleomycin IV on
days 1, 8, and 15.
- Arm II: Patients receive cisplatin, etoposide, and bleomycin as in arm I and paclitaxel
IV over 3 hours on day 1. Patients also receive filgrastim (G-CSF) subcutaneously on
days 6-15.
In both arms, treatment repeats every 3 weeks for a total of 4 courses in the absence of
disease progression or unacceptable toxicity.
Quality of life is assessed before treatment randomization and at 1 and 2 years after
randomization.
Patients are followed monthly for 1 year, every 2 months for 1 year, every 3 months for 1
year, every 6 months for 1 year, and then annually thereafter.
PROJECTED ACCRUAL: A total of 84-164 patients (42-82 per treatment arm) will be accrued for
the phase II study. A total of 498 patients (249 per treatment arm) will be accrued for the
phase III study. Accrual will be completed within 4 years.
;
Allocation: Randomized, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00788125 -
Dasatinib, Ifosfamide, Carboplatin, and Etoposide in Treating Young Patients With Metastatic or Recurrent Malignant Solid Tumors
|
Phase 1/Phase 2 | |
| Withdrawn |
NCT00006126 -
Peripheral Stem Cell Transplantation in Treating Patients With Melanoma or Small Cell Lung, Breast, Testicular, or Kidney Cancer That is Metastatic or That Cannot Be Treated With Surgery
|
Phase 1 | |
| Completed |
NCT00003173 -
High-Dose Thiotepa Plus Peripheral Stem Cell Transplantation in Treating Patients With Refractory Solid Tumors
|
Phase 2 | |
| Completed |
NCT00002596 -
Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors
|
Phase 3 | |
| Not yet recruiting |
NCT03448822 -
Sentinel Lymph Node Procedure in Testicular Germ Cell Tumour
|
||
| Completed |
NCT01433224 -
Studying Biomarkers in Samples From Younger Patients With Malignant Germ Cell Tumor Progression
|
N/A | |
| Recruiting |
NCT01172912 -
High-Dose Chemotherapy and Stem Cell Transplant in Treating Patients With Metastatic Germ Cell Tumors That Have Not Responded to First-Line Therapy
|
Phase 2 | |
| Completed |
NCT00293384 -
Aprepitant, Granisetron, & Dexamethasone in Preventing Nausea & Vomiting in Pts. Receiving Cyclophosphamide Before a Stem Cell Transplant
|
N/A | |
| Completed |
NCT00019331 -
Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors
|
Phase 2 | |
| Completed |
NCT00003107 -
Interleukin-12 in Treating Patients With Hematologic Cancers or Solid Tumors
|
Phase 1 | |
| Completed |
NCT00002515 -
Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Rare Cancer
|
Phase 2 | |
| Recruiting |
NCT06133699 -
Sentinel Lymph Node Biopsy in Stage AI-IIA Germ Cell Tumors
|
N/A | |
| Recruiting |
NCT05670938 -
Follow-up After Surgery for Testicular Cancer
|
||
| Active, not recruiting |
NCT00104676 -
Combination Chemotherapy in Treating Patients With Stage II or Stage III Germ Cell Tumors
|
Phase 3 | |
| Recruiting |
NCT00551122 -
Gemcitabine, Paclitaxel, Ifosfamide, and Cisplatin in Treating Patients With Progressive or Relapsed Metastatic Germ Cell Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00002508 -
Combination Chemotherapy Followed by Bone Marrow or Stem Cell Transplantation in Treating Patients With Relapsed or Refractory Germ Cell Tumors
|
Phase 1/Phase 2 | |
| Completed |
NCT00003800 -
Diagnostic Study of Patients With Stage I Testicular Cancer
|
N/A | |
| Terminated |
NCT05012397 -
Milademetan in Advanced/Metastatic Solid Tumors
|
Phase 2 | |
| Completed |
NCT00007813 -
Peripheral Stem Cell Transplantation Plus Chemotherapy in Treating Patients With Malignant Solid Tumors
|
Phase 1 | |
| Terminated |
NCT00324324 -
Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant
|
Phase 3 |